Kuros Biosciences Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 213

Employees

  • Stock Symbol
  • KURN

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $23.29
  • (As of Friday Closing)

Kuros Biosciences General Information

Description

Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.

Contact Information

Formerly Known As
Kuros Biosurgery
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Wagistrasse 25
  • Schlieren
  • 8952 Zurich
  • Switzerland
+41 044
Primary Industry
Surgical Devices
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
SWX
Vertical(s)
Corporate Office
  • Wagistrasse 25
  • Schlieren
  • 8952 Zurich
  • Switzerland
+41 044

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kuros Biosciences Stock Performance

As of 13-Nov-2026, Kuros Biosciences’s stock price is $23.29. Its current market cap is $926M with 39.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.29 $23.67 $19.95 - $40.36 $926M 39.8M 224K $0.23

Kuros Biosciences Financials Summary

As of 30-Jun-2026, Kuros Biosciences has a trailing 12-month revenue of $175M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 924,928 1,339,671 875,715 135,019
Revenue 174,932 146,058 85,159 37,338
EBITDA 9,118 8,652 (817) (8,052)
Net Income 8,969 2,551 (4,835) (11,298)
Total Assets 148,944 133,875 92,702 85,082
Total Debt 10,067 1,390 1,966 2,551
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kuros Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kuros Biosciences‘s full profile, request access.

Request a free trial

Kuros Biosciences Patents

Kuros Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022217100-A1 Porous osteoinductive composites Active 02-Feb-2021
AU-2022217100-B2 Porous osteoinductive composites Active 02-Feb-2021
EP-4288122-A1 Porous osteoinductive composites Pending 02-Feb-2021
JP-2025130730-A Porous osteoinductive composites Pending 02-Feb-2021
US-20240131226-A1 Porous osteoinductive composites Pending 02-Feb-2021 A61L27/46
To view Kuros Biosciences’s complete patent history, request access »

Kuros Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kuros Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kuros Biosciences‘s full profile, request access.

Request a free trial

Kuros Biosciences Acquisitions (2)

Kuros Biosciences’s most recent deal was a Merger/Acquisition with Xpand Biotechnology for . The deal was made on 23-Jan-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Xpand Biotechnology 23-Jan-2017 Merger/Acquisition Discovery Tools (Healthcare)
Cytos Biotechnology 18-Jan-2016 Merger/Acquisition Drug Discovery
To view Kuros Biosciences’s complete acquisitions history, request access »

Kuros Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Devices

Subindustry

Rank

Percentile

To view Kuros Biosciences’s complete esg history, request access »

Kuros Biosciences FAQs

  • When was Kuros Biosciences founded?

    Kuros Biosciences was founded in 2000.

  • Where is Kuros Biosciences headquartered?

    Kuros Biosciences is headquartered in Zurich, Switzerland.

  • What is the size of Kuros Biosciences?

    Kuros Biosciences has 213 total employees.

  • What industry is Kuros Biosciences in?

    Kuros Biosciences’s primary industry is Surgical Devices.

  • Is Kuros Biosciences a private or public company?

    Kuros Biosciences is a Public company.

  • What is Kuros Biosciences’s stock symbol?

    The ticker symbol for Kuros Biosciences is KURN.

  • What is the current stock price of Kuros Biosciences?

    As of 13-Nov-2026 the stock price of Kuros Biosciences is $23.29.

  • What is the current market cap of Kuros Biosciences?

    The current market capitalization of Kuros Biosciences is $926M.

  • What is Kuros Biosciences’s current revenue?

    The trailing twelve month revenue for Kuros Biosciences is $175M.

  • What is Kuros Biosciences’s annual earnings per share (EPS)?

    Kuros Biosciences’s EPS for 12 months was $0.23.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process